Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care

Conditions

Bacteremia, Hospital Acquired Condition, Resistance Bacterial, Sepsis

Keywords

Hospital-acquired infection, Blood stream infection, Bacteremia, Intensive care

Brief summary

Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.

Detailed description

Eurobact II is a multinational multicentre cohort study that will include patients with hospital-acquired blood stream infections (HA-BSI) treated in ICUs around the globe. It will provide with an update of the epidemiology of HA-BSI since the Eurobact I study. It is designed to investigate the effects of HA-BSI on mortality at day 28. To describe the determinants of outcomes of HA-BSI, specifically the effects of the source of infection, the microorganism, the characteristics of antimicrobial therapy and of source control. It will investigate patient specific and organizational factors and will describe the determinants of management of HA-BSI in ICUs.

Gajdos L, Buetti N, Tabah A, Ruckly S, Akova M, Sjöval F, Arvaniti K, de Waele J, Bracht H, Barbier F, Timsit JF, EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP) and the OUTCOMEREA Network.

2025-03-014 citations

10.1007/s00134-025-07857-6

Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study.

Buetti N, Tabah A, Loiodice A, Ruckly S, Aslan AT, Montrucchio G, Cortegiani A, Saltoglu N, Kayaaslan B, Aksoy F, Murat A, Akdoğan Ö, Saracoglu KT, Erdogan C, Leone M, Ferrer R, Paiva JA, Hayashi Y, Ramanan M, Conway Morris A, Barbier F, Timsit JF, Eurobact 2 study group.

2022-10-1838 citations

10.1186/s13054-022-04166-y

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Age \> 18 Years. * Hospital Acquired Bloodstream Infection (HA-BSI). * Treated in the ICU. * ICU acquired OR * Hospital acquired prior to ICU admission

Exclusion criteria

* Patients that had a positive blood culture in the hospital and transferred to ICU for a different reason than specific treatment of the causes or consequences of HA-BSI. * Previous inclusion in the study. * HA-BSI is defined as a positive blood culture (BC) sampled after 48 hours following hospital admission.

Design outcomes

Primary

Measure	Time frame	Description
Mortality	28 days	Vital status

Secondary

Measure	Time frame	Description
Clinical cure	7 days, 28 days	As evaluated by the treating clinician
Microbiological cure	7 days, 28 days	Presence of persisting or relapsing blood stream infection
Progress of organ failures	7 days	Assessed by the components of the SOFA score
Days free or organ supportive therapy	28 days	Days free of renal replacement therapy, mechanical ventilation, vasopressors, intensive care unit

Countries

Australia, France

Outcome results